These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 31194989)

  • 1. A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: Therapeutic efficacy of proton pump inhibitors.
    Bertoni A; Carta S; Baldovini C; Penco F; Balza E; Borghini S; Di Duca M; Ognio E; Signori A; Nozza P; Schena F; Castellani P; Pastorino C; Perrone C; Obici L; Martini A; Ceccherini I; Gattorno M; Rubartelli A; Chiesa S
    J Allergy Clin Immunol; 2020 Jan; 145(1):368-378.e13. PubMed ID: 31194989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Knock-In Mouse Model of Cryopyrin-Associated Periodic Syndromes.
    Bertoni A; Prigione I; Chiesa S; Ceccherini I; Gattorno M; Rubartelli A
    Methods Mol Biol; 2023; 2696():281-297. PubMed ID: 37578730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance.
    Balza E; Piccioli P; Carta S; Lavieri R; Gattorno M; Semino C; Castellani P; Rubartelli A
    Cell Death Dis; 2016 Jul; 7(7):e2304. PubMed ID: 27441656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Mutation in the Pyrin Domain of the NOD-like Receptor Family Pyrin Domain Containing Protein 3 in Muckle-Wells Syndrome.
    Hu J; Zhu Y; Zhang JZ; Zhang RG; Li HM
    Chin Med J (Engl); 2017 Mar; 130(5):586-593. PubMed ID: 28229991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel evidences of atypical manifestations in cryopyrin-associated periodic syndromes.
    Bujan-Rivas S; Basagaña M; Sena F; Méndez M; Dordal MT; Gonzalez-Roca E; Ruiz-Ortiz E; Mensa-Vilaró A; Plaza S; Modesto C; Ordi-Ros J; Yagüe J; Martínez-Valle F; Aróstegui JI
    Clin Exp Rheumatol; 2017; 35 Suppl 108(6):27-31. PubMed ID: 28079503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Molecular Phenotypes of Low-Penetrance Variants of NLRP3: Diagnostic and Therapeutic Challenges.
    Kuemmerle-Deschner JB; Verma D; Endres T; Broderick L; de Jesus AA; Hofer F; Blank N; Krause K; Rietschel C; Horneff G; Aksentijevich I; Lohse P; Goldbach-Mansky R; Hoffman HM; Benseler SM
    Arthritis Rheumatol; 2017 Nov; 69(11):2233-2240. PubMed ID: 28692792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies.
    Brydges SD; Broderick L; McGeough MD; Pena CA; Mueller JL; Hoffman HM
    J Clin Invest; 2013 Nov; 123(11):4695-705. PubMed ID: 24084736
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Nakanishi H; Kawashima Y; Kurima K; Chae JJ; Ross AM; Pinto-Patarroyo G; Patel SK; Muskett JA; Ratay JS; Chattaraj P; Park YH; Grevich S; Brewer CC; Hoa M; Kim HJ; Butman JA; Broderick L; Hoffman HM; Aksentijevich I; Kastner DL; Goldbach-Mansky R; Griffith AJ
    Proc Natl Acad Sci U S A; 2017 Sep; 114(37):E7766-E7775. PubMed ID: 28847925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
    Vande Walle L; Stowe IB; Šácha P; Lee BL; Demon D; Fossoul A; Van Hauwermeiren F; Saavedra PHV; Šimon P; Šubrt V; Kostka L; Stivala CE; Pham VC; Staben ST; Yamazoe S; Konvalinka J; Kayagaki N; Lamkanfi M
    PLoS Biol; 2019 Sep; 17(9):e3000354. PubMed ID: 31525186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice.
    Kaufmann B; de Los Reyes Jiménez M; Booshehri LM; Onyuru J; Leszczynska A; Uri A; Michel S; Klar R; Jaschinski F; Feldstein AE; Broderick L; Hoffman HM
    J Immunol; 2023 Jul; 211(2):287-294. PubMed ID: 37256266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell stress increases ATP release in NLRP3 inflammasome-mediated autoinflammatory diseases, resulting in cytokine imbalance.
    Carta S; Penco F; Lavieri R; Martini A; Dinarello CA; Gattorno M; Rubartelli A
    Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2835-40. PubMed ID: 25730877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nlrp3 inflammasome activation in macrophages suffices for inducing autoinflammation in mice.
    Frising UC; Ribo S; Doglio MG; Malissen B; van Loo G; Wullaert A
    EMBO Rep; 2022 Jul; 23(7):e54339. PubMed ID: 35574994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel Nlrp3 knock-in mouse model with hyperactive inflammasome in development of lethal inflammation.
    Zhou Y; Yang X; Zhu L
    Clin Exp Immunol; 2024 Feb; 215(2):202-214. PubMed ID: 37594231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
    Landmann EC; Walker UA
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AA amyloidosis complicating cryopyrin-associated periodic syndrome: a study of 86 cases including 23 French patients and systematic review.
    Rodrigues F; Cuisset L; Cador-Rousseau B; Giurgea I; Neven B; Buob D; Quartier P; Hachulla E; Lequerré T; Cam G; Boursier G; Hervieu V; Grateau G; Georgin-Lavialle S
    Rheumatology (Oxford); 2022 Nov; 61(12):4827-4834. PubMed ID: 35262642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two adult siblings with atypical cryopyrin-associated periodic syndrome due to a novel M299V mutation in NLRP3.
    Verma D; Eriksson P; Sahdo B; Persson A; Ejdebäck M; Särndahl E; Söderkvist P
    Arthritis Rheum; 2010 Jul; 62(7):2138-43. PubMed ID: 20506209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anakinra for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2014 Jan; 10(1):7-18. PubMed ID: 24308832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-frequency mosaicism in cryopyrin-associated periodic fever syndrome: mosaicism in systemic autoinflammatory diseases.
    Nishikomori R; Izawa K; Kambe N; Ohara O; Yasumi T
    Int Immunol; 2019 Sep; 31(10):649-655. PubMed ID: 31185077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NLRP3 inflammasome and NLRP3-related autoinflammatory diseases: From cryopyrin function to targeted therapies.
    Moltrasio C; Romagnuolo M; Marzano AV
    Front Immunol; 2022; 13():1007705. PubMed ID: 36275641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canakinumab for the treatment of cryopyrin-associated periodic syndromes.
    Walsh GM
    Drugs Today (Barc); 2009 Oct; 45(10):731-5. PubMed ID: 20069137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.